Epigenomic deregulation in the immune system

Epigenomics

Volumn 3, Issue 6, 2011, Pages 697-713

  Rodriguez Cortez, Virginia C ^a   Hernando, Henar ^a   De La Rica, Lorenzo ^a   Vento, Roser ^a   Ballestar, Esteban ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

autoimmune; DNA methylation; epigenetics; immune system; immunodeficiency; lymphocyte; miRNAs

Indexed keywords

MICRORNA;

AUTOIMMUNE DISEASE; DNA METHYLATION; EPIGENETICS; EPSTEIN BARR VIRUS; GENE CONTROL; GENE EXPRESSION; GENETIC PREDISPOSITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOPATHOLOGY; MUTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION;

CHROMATIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; EPSTEIN-BARR VIRUS INFECTIONS; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM DISEASES; LYMPHOCYTES; MODELS, IMMUNOLOGICAL; MUTATION;

EID: 82455167273     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.11.99     Document Type: Review

References (148)

1. Abbas A, Janeway CA Jr. Immunology: improving on nature review in the twenty-first century. Cell 100(1), 129-138 (2000).
2. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91(3), 295-298 (1997).
3. Medzhitov R, Janeway CA Jr. Innate Immunity. N. Engl. J. Med. 343, 338-344 (2000).
4. Cruvinel Wde M, Mesquita D Jr, Araújo JA et al. Immune system - part I. Fundamentals of innate immunity with emphasis on molecular and cellular mechanisms of inflammatory response. Rev. Bras. Reumatol. 50(4), 434-461 (2010).
5. Bonilla F, Oettgen HC. Adaptive immunity. J. Allergy.Clin. Immunol. 125(2), S33-S40 (2010).
6. Medzdhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9(1), 4-9 (1997).
7. Orkin SH. Diversification of haematopoietic stem cells to specific lineages. Nat. Rev. 1(1), 57-64 (2000).
8. Hewagama A, Richardson B. The genetics and epigenetics of autoimmune diseases. J. Autoimmunity 33(1), 3-11 (2009).
9. Delgado-Vega A, Sánchez E, Löfgren S, Castillejo-López C, Alarcón-Riquelme ME. Recent findings on genetics of systemic autoimmune diseases. Curr. Opin. Immunol. 22(6), 698-705 (2010).
10. Conley ME, Dobbs AK, Farmer DM et al. Primary B cell immunodeficiencies: comparisons and contrasts. Ann. Rev. Immunol. 27, 199-227 (2009).
11. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008).
12. Irizarry RA, Ladd-Acosta C, Wen B et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41(2), 178-186 (2009).
13. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 74, 481-514 (2005).
14. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr. Opin. Oncol. 20(6), 705-710 (2008).
15. Bhutani N, Brady JJ, Damian M, Sacco A, Corbel SY, Blau HM. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 463(7284), 1042-1047 (2010).
16. Bruniquel D, Schwartz RH. Selective, stable demethylation of the interleukin 2 gene enhances transcription by an active process. Nat. Immunol. 4(3), 235-240 (2003).
17. Ooi SK, Bestor TH. The colorful history of active DNA demethylation. Cell 133(7), 1145-1148 (2008).
18. Fritz EL, Papavasiliou FN. Cytidine deaminases: AIDing DNA demethylation? Genes Dev. 24(19), 2107-2114 (2010).
19. Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 135(7), 1201-1212 (2008).
20. Tahiliani M, Koh KP, Shen Y et al. Conversion of 5 methylcytosine to 5 hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324 (5929), 930-935 (2009).
21. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466(7310), 1129-1133 (2010).
22. Ito S, Shen L, Dai Q et al. Tet proteins can convert 5 methylcytosine to 5 formylcytosine and 5 carboxylcytosine. Science 333(6047), 1300-1303 (2011).
23. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693-705 (2007).
24. Allis CD, Berger SL, Cote J et al. New nomenclature for chromatin-modifying enzymes. Cell 131(4), 633-636 (2007).
25. Biancotto C, Frigè G, Minucci S. Histone modification therapy of cancer. Adv. Genet. 70, 341-386 (2010).
26. Ballestar E, Esteller M. The impact of chromatin in human cancer. linking DNA methylation to gene silencing. Carcinogenesis 23, 1103-1109 (2002).
27. Müller J, Verrijzer P. Biochemical mechanisms of gene regulation by Polycomb group protein complexes. Curr. Opin. Genet. Dev. 19, 150-158 (2009).
28. Fabbri M, Calin GA. Epigenetics and miRNAs in human cancer. Adv. Genet. 70, 87-99 (2010).
29. Davidson A, Diamond B. Autoimmune diseases. N. Engl. J. Med. 345(5), 340-350 (2001).
30. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435(7042), 590-597 (2005).
31. Lie BA, Thorsby E. Several genes in the extended human MHC contribute to predisposition to autoimmune diseases. Curr. Opin. Immunol. 17(5), 526-531 (2005).
32. Delgado-Vega A, Sanchez E, Lofgren S, Castillejo-Lopez C, Alarcon-Riquelme ME. Recent findings on genetics of systemic autoimmune diseases. Curr. Opin. Immunol. 22(6), 698-705 (2010).
33. Silman AJ, Macgregor AJ, Thomson W et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br. J. Rheumatol. 32(10), 903-907 (1993).
34. Grennan DM, Parfitt A, Manolios N et al. Family and twin studies in systemic lupus erythematosus. Dis. Markers 13(2), 93-98 (1997).
35. Aho K, Koskenvuo M, Tuominen J, Kaprio J. Occurrence of rheumatoid arthritis in a nationwide series of twins. J. Rheumatol. 13(5), 899-902 (1986).
36. + cells. Hum. Immunol. 17(4), 456-470 (1986).
37. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140(7), 2197-2200 (1988).
38. Richardson BC, Strahler JR, Pivirotto TS et al. Phenotypic and functional similarities between 5 azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum. 35(6), 647-662 (1992).
39. Ballestar E. Epigenetic alterations in autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 7(5), 263-271 (2011).
40. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 33(11), 1665-1673 (1990).
41. Harmon CE, Portanova JP. Drug-induced lupus: clinical and serological studies. Clin. Rheum. Dis. 8(1), 121-135 (1982).
42. + T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand. J. Rheumatol. 38(5), 369-374 (2009).
43. + T cells with either of two distinct DNA methyltransferase inhibitors, 5 azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J. Clin. Invest. 92(1), 38-53 (1993).
44. Javierre BM, Fernandez AF, Richter J et al. Changes in the pattern of DNA methylation associate with twin discordance in systemiclupus erythematosus. Genome Res. 20(2), 170-179 (2010).
45. + T cells from patients with systemic lupus erythematosus. Epigenetics 6(5), 593-601 (2011).
46. Neumann E, Lefevre S, Zimmermann B, Gay S, Muller-Ladner U. Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol. Med. 16(10), 458-468 (2010).
47. Corvetta A, Della Bitta R, Luchetti Mm, Pomponio G. 5 methylcytosine content of DNA in blood, synovial mononuclear cells and synovial tissue from patients affected by autoimmune rheumatic diseases. J. Chromatogr. 566(2), 481-491 (1991).
48. Neidhart M, Rethage J, Kuchen S et al. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum. 43(12), 2634-2647 (2000).
49. Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 60(12), 3613-3622 (2009).
50. Neidhart M et al. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue. association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum. 43, 2634-2647 (2000).
51. Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 60, 3613-3622 (2009).
52. Kuchen S, Seemayer CA, Rethage J et al. The L1 retroelement-related p40 protein induces p38d MAP kinase. Autoimmunity 37(1), 57-65 (2004).
53. Stanczyk J, Ospelt C, Karouzakis E et al. Altered expression of microRNA 203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum. 63(2), 373-381 (2011).
54. Takami N, Osawa K, Miura Y et al. Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells. Arthritis Rheum. 54(3), 779-787 (2006).
55. + T cells. J. Rheumatol. 35(5), 804-810 (2008).
56. Mishra N, Brown DR, Olorenshaw IM, Kammer GM. Trichostatin A reverses skewed expression of CD154, interleukin 10, and interferon g gene and protein expression in lupus T cells. Proc. Natl Acad. Sci. USA 98(5), 2628-2633 (2001).
57. Kawabata T, Nishida K, Takasugi K et al. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor a in synovial tissue of rheumatoid arthritis. Arthritis Res. Ther. 12(4), R133 (2010).
58. Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J. Rheumatol. 36(8), 1580-1589 (2009).
59. Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8(5), 707-717 (2003).
60. Nishida K, Komiyama T, Miyazawa S et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/ Cip1) expression. Arthritis Rheum. 50(10), 3365-3376 (2004).
61. Lin HS, Hu CY, Chan HY et al. Antirheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150(7), 862-872 (2007).
62. Nasu Y, Nishida K, Miyazawa S et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 16(6), 723-732 (2008).
63. Choo QY, Ho PC, Tanaka Y, Lin HS. Histone deacetylase inhibitors MS 275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology (Oxford) 49(8), 1447-1460 (2010).
64. Jüngel A, Baresova V, Ospelt C et al. Trichostatin A sensitizes rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann. Rheum. Dis. 65(7), 910-912 (2006).
65. Morinobu A, Wang B, Liu J, Yoshiya S, Kurosaka M, Kumagai S. Trichostatin A cooperates with Fas-mediated signal to induce apoptosis in rheumatoid arthritis synovial fibroblasts. J. Rheumatol. 33(6), 1052-1060 (2006).
66. Zhou X, Hua X, Ding X, Bian Y, Wang X. Trichostatin differentially regulates Th1 and Th2 responses and alleviates rheumatoid arthritis in mice. J. Clin. Immunol. 31(3), 395-405 (2011).
67. Schroeder TM, Nair AK, Staggs R, Lamblin AF, Westendorf JJ. Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors. BMC Genomics 8, 362 (2007).
68. Nakamura T, Kukita T, Shobuike T et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN b production. J. Immunol. 175(9), 5809-5816 (2005).
69. Vojinovic J, Damjanov N, D'urzo C et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63(5), 1452-1458 (2011).
70. Trenkmann M, Brock M, Gay RE et al. Expression and function of EZH2 in synovial fibroblasts. Epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis. Ann. Rheum. Dis. 70, 1482-1488 (2011).
71. Baranzini SE, Mudge J, van Velkinburgh JC et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 464(7293), 1351-1356 (2010).
72. Maródi L, Notarangelo LD. Immunological and genetic bases of new primary immunodeficiencies. Nat. Rev. Immunol. 7(11), 851-861 (2007).
73. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J. Allergy Clin. Immunol. 125(2), S195-S203 (2010).
74. Notarangelo LD. Primary immunodeficiencies. J. Allergy Clin. Immunol. 125(2), S182-S194 (2010).
75. Hansen RS, Wijmenga C, Luo P et al. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc. Natl Acad. Sci. USA 96, 14412-14417 (1999).
76. Ehrlich M, Sanchez C, Shao C et al. ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation. Autoimmunity 41, 253-271 (2008).
77. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 74, 481-514 (2005).
78. Jin B, Tao Q, Peng J. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. Hum. Mol. Genet. 17(5), 690-709 (2008).
79. Erlich M, Buchanan F, Tsien G et al. DNA methyltransferase 3B mutations linked to the ICF syndrome cause dysregulation of lymphocyte migration, activation and survival genes. Hum. Mol. Genet. 10(25), 2917-2931 (2001).
80. Gatto S, Ragione FD, Cimmino A et al. Epigenetic alteration of microRNAs in DNMT3B-mutated patients of ICF syndrome. Epigenetics 5(5), 427-443 (2010).
81. Revy P, Muto E, Levy Y et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper IgM syndrome (HIGM2).Cell 102(5), 565-575 (2000).
82. Muramatsu M, Sankaranand VS, Anant S et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem. 274(26), 18470-18476 (1999).
83. Morgan HD, Dean W, Coker HA, Reik W, Petersen-Mahrt SK. Activation-induced cytidine deaminase deaminates 5 methylcytosine in DNA and is expressed in pluripotent tissues. J. Biol. Chem. 279(50), 52353-52360 (2004).
84. Popp C, Dean W, Feng S et al. Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by aid deficiency. Nature 463(7284), 1101-1105 (2010).
85. Bhutani N, Brady JJ, Damian M, Sacco A, Corbel SY, Blau HM. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 463(7284), 1042-1047 (2010).
86. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27(3), 406-416 (2007).
87. Da Silva SR, De Oliveira DE. HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies. Cancer Lett. 305(2), 175-185 (2011).
88. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer. 4(10), 757-768 (2004).
89. Yin Y, Manoury B, Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301(5638), 1371-1374 (2003).
90. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 24(11), 584-588 (2003).
91. James JA, Neas BR, Moser KL et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 44(5), 1122-1126 (2001).
92. Poole BD, Scofield RH, Harley JB, James JA. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 39(1), 63-70 (2006).
93. Serafini B, Severa M, Columba-Cabezas S et al. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B cell activation. J. Neuropathol. Exp. Neurol. 69(7), 677-693 (2010).
94. Kintner C, Sugden B. Conservation and progressive methylation of Epstein-Barr viral DNA sequences in transformed cells. J. Virol. 38(1), 305-316 (1981).
95. Dyson PJ, Farrell PJ. Chromatin structure of Epstein-Barr virus. J. Gen. Virol. 66(Pt 9), 1931-1940 (1985).
96. Minarovits J, Minarovits-Kormuta S, Ehlin-Henriksson B, Falk K, Klein G, Ernberg I. Host cell phenotype-dependent methylation patterns of Epstein-Barr virus DNA. J. Gen. Virol. 72(Pt 7), 1591-1599 (1991).
97. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc. Natl Acad. Sci. USA 108(5), 1919-1924 (2011).
98. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ. Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog. 5(6), e1000492 (2009).
99. Caliskan M, Cusanovich DA, Ober C, Gilad Y. The effects of EBV transformation on gene expression levels and methylation profiles. Hum. Mol. Genet. 20(8), 1643-1652 (2011).
100. Pfeffer S, Zavolan M, Grasser FA et al. Identification of virus-encoded microRNAs. Science 304(5671), 734-736 (2004).
101. Barth S, Pfuhl T, Mamiani A et al. Epstein- Barr virus-encoded microRNA miR BART2 downregulates the viral DNA polymerase BALF5. Nucleic Acids. Res. 36(2), 666-675 (2008).
102. Lo AK, To KF, Lo KW et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc. Natl Acad. Sci. USA 104(41), 16164-16169 (2007).
103. Lung RW, Tong JH, Sung YM et al. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR BART22. Neoplasia 11(11), 1174-1184 (2009).
104. Choy EY, Siu KL, Kok KH et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J. Exp. Med. 205(11), 2551-2560 (2008).
105. Marquitz AR, Mathur A, Nam CS, Raab- Traub N. The Epstein-Barr virus BART microRNAs target the proapoptotic protein Bim. Virology 412(2), 392-400 (2011).
106. Xia T, O'hara A, Araujo I et al. EBV microRNAs in primary lymphomas and targeting of CXCL 11 by EBV-miR BHRF1-3. Cancer Res. 68(5), 1436-1442 (2008).
107. Cameron JE, Fewell C, Yin Q et al. Epstein-Barr virus growth/latency III program alters cellular microRNA expression. Virology 382(2), 257-266 (2008).
108. Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA, Cullen BR. Virally induced cellular microRNA miR 155 plays a key role in B cell immortalization by Epstein-Barr virus. J. Virol. 84(22), 11670-11678 (2010).
109. Mrazek J, Kreutmayer SB, Grasser FA, Polacek N, Huttenhofer A. Subtractive hybridization identifies novel differentially expressed ncRNA species in EBV-infected human B cells. Nucleic Acids Res. 35(10), e73 (2007).
110. Cameron JE, Yin Q, Fewell C et al. Epstein-Barr virus latent membrane protein 1 induces cellular miRNA miR 146a, a modulator of lymphocyte signaling pathways. J. Virol. 82(4), 1946-1958 (2008).
111. Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M. Epstein-Barr virus latent membrane protein 1 trans-activates miR 155 transcription through the NF-kB pathway. Nucleic Acids Res. 36(20), 6608-6619 (2008).
112. Motsch N, Pfuhl T, Mrazek J, Barth S, Grasser FA. Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular miRNA miR 146a. RNA Biol. 4(3), 131-137 (2007).
113. Yin Q, Wang X, Fewell C et al. MiRNA miR 155 inhibits bone morphogenetic protein (BMP) signaling and BMP-mediated Epstein-Barr virus reactivation. J. Virol. 84(13), 6318-6327 (2010).
114. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV 1 infection. Nat. Med. 9(7), 867-873 (2003).
115. Coleman CM, Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 6, 51 (2009).
116. Zhu T, Wang N, Carr A et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J. Virol. 70(5), 3098-3107 (1996).
117. Cheng-Mayer C, Weiss C, Seto D, Levy JA. Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. Proc. Natl Acad. Sci. USA 86(21), 8575-8579 (1989).
118. Alexaki A, Wigdahl B. HIV 1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathog. 4(12), e1000215 (2008).
119. Liszewski MK, Yu JJ, O'doherty U. Detecting HIV 1 integration by repetitive-sampling Alu-gag PCR. Methods 47(4), 254-260 (2009).
120. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV 1 integration in the human genome favors active genes and local hotspots. Cell 110(4), 521-529 (2002).
121. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. Epigenetic regulation of HIV 1 latency by cytosine methylation. PLoS Pathog 5(6), e1000495 (2009).
122. El Kharroubi A, Piras G, Zensen R, Martin MA. Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol. Cell. Biol. 18(5), 2535-2544 (1998).
123. Blazkova J, Trejbalova K, Gondois-Rey F et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 5(8), e1000554 (2009).
124. Fang JY, Mikovits JA, Bagni R, Petrow- Sadowski CL, Ruscetti FW. Infection of lymphoid cells by integration-defective human immunodeficiency virus type 1 increases de novo methylation. J. Virol. 75(20), 9753-9761 (2001).
125. Kwon HS, Brent MM, Getachew R et al. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 3(3), 158-167 (2008).
126. Triboulet R, Mari B, Lin YL et al. Suppression of microRNA-silencing pathway by HIV 1 during virus replication. Science 315(5818), 1579-1582 (2007).
127. Klase Z, Kale P, Winograd R et al. HIV 1 TAR element is processed by Dicer to yield a viral miRNA involved in chromatin remodeling of the viral LTR. BMC Mol. Biol. 8, 63 (2007).
128. Lu Q, Kaplan M, Ray D et al. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum. 46(5), 1282-1291 (2002).
129. Lu Q, Wu A, Tesmer L, Ray D, Yousif N, Richardson B. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J. Immunol. 179(9), 6352-6358 (2007).
130. Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J. Immunol. 174(10), 6212-6219 (2005).
131. + lupus T cells. J. Immunol. 172(6), 3652-3661 (2004).
132. Garaud S, Le Dantec C, Jousse-Joulin S et al. IL 6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J. Immunol. 182(9), 5623-5632 (2009).
133. Nile CJ, Read RC, Akil M, Duff GW, Wilson AG. Methylation status of a single CpG site in the IL 6 promoter is related to IL 6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum. 58(9), 2686-2693 (2008).
134. Mastronardi FG, Noor A, Wood DD, Paton T, Moscarello MA. Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. J. Neurosci. Res. 85(9), 2006-2016 (2007).
135. Gonzalez S, Aguilera S, Alliende C et al. Alterations in type I hemidesmosome components suggestive of epigenetic control in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 63(4), 1106-1115 (2011).
136. + T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand. J. Rheumatol. 38(5), 369-374 (2009).
137. Wang Y, Fan Ps, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 54(7), 2271-2279 (2006).
138. Ozbalkan Z, Bagislar S, Kiraz S et al. Skewed X chromosome inactivation in blood cells of women with scleroderma. Arthritis Rheum. 52(5), 1564-1570 (2005).
139. Chen M, Chen ZQ, Cui PG et al. The methylation pattern of p16INK4a gene promoter in psoriatic epidermis and its clinical significance. Br. J. Dermatol. 158(5), 987-993 (2008).
140. Zhang P, Su Y, Chen H, Zhao M, Lu Q. Abnormal DNA methylation in skin lesions and PBMCs of patients with psoriasis vulgaris. J. Dermatol. Sci. 60(1), 40-42 (2010).
141. Ruchusatsawat K, Wongpiyabovorn J, Shuangshoti S, Hirankarn N, Mutirangura A. SHP 1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis. J. Mol. Med. 84(2), 175-182 (2006).
142. Zhang K, Zhang R, Li X, Yin G, Niu X. Promoter methylation status of p15 and p21 genes in HPP CFCs of bone marrow of patients with psoriasis. Eur. J. Dermatol. 19(2), 141-146 (2009).
143. Zhang K, Zhang R, Li X, Yin G, Niu X, Hou R. The mRNA expression and promoter methylation status of the p16 gene in colony-forming cells with high proliferative potential in patients with psoriasis. Clin. Exp. Dermatol. 32(6), 702-708 (2007).
144. Gloria L, Cravo M, Pinto A et al. DNA hypomethylation and proliferative activity are increased in the rectal mucosa of patients with long-standing ulcerative colitis. Cancer 78(11), 2300-2306 (1996).
145. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res. 58(17), 3942-3945 (1998).
146. Sato F, Harpaz N, Shibata D et al. Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res. 62(4), 1148-1151 (2002).
147. Tahara T, Shibata T, Nakamura M et al. Effect of MDR1 gene promoter methylation in patients with ulcerative colitis. Int. J. Mol. Med. 23(4), 521-527 (2009).
148. Brix TH, Knudsen GP, Kristiansen M, Kyvik KO, Orstavik KH, Hegedus L. High frequency of skewed X chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J. Clin. Endocrinol. Metab. 90(11), 5949-5953 (2005).